Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages (Q44471231)

3 December 2017

Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages (English)

1 reference

3 December 2017

0 references

0 references

8

1 reference

3 December 2017

Francesco Di Mario

1

1 reference

3 December 2017

Nadia Dal Bo

2

1 reference

3 December 2017

Giovanni Aragona

3

1 reference

3 December 2017

Ali M Moussa

4

1 reference

3 December 2017

Veronica Iori

5

1 reference

3 December 2017

Giulia M Cavestro

6

1 reference

3 December 2017

Alberto Pilotto

7

1 reference

3 December 2017

Marilisa Franceschi

9

1 reference

3 December 2017

Massimo Rugge

10

1 reference

3 December 2017

Angelo Franze

11

1 reference

3 December 2017

1 July 2003

1 reference

Journal of Gastroenterology and Hepatology

3 December 2017

1 reference

3 December 2017

18

1 reference

3 December 2017

7

1 reference

3 December 2017

783-786

1 reference

Current role of acid suppressants in Helicobacter pylori eradication therapy

3 December 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Efficacy of a multistep strategy for Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Regular review: treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Current regimens for treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03035.X

10.1046/J.1440-1746.2003.03035.X

21 January 2018

Identifiers

DOI

1 reference

release_cd46udzdxbgjdd7nh4r6rpqayq

3 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cd46udzdxbgjdd7nh4r6rpqayq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference